Phase III Randomized, Intergroup Trial Assessing the Clinical Activity Of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the Kit Receptor Tyrosine Kinase (CD117).
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Dec 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 04 Jul 2014 10-year survival results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.